Stockreport

Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF FT819 manufacturing: Fate uses a clonal master cell bank approach for its off-the-shelf CD8 CAR T, claiming a single bank could yield 10 million doses and the current f [Read more]